Potential treatment options for primary CRC were recently reviewed [96] and include immune and adjuvant therapy depending on the CIMP-status for CMS1 (and possibly LMS1), targeted treatment to MAPK- and WNT-pathways, MYC-expression or glycolysis metabolism for CMS2 and/or CMS3 (and possibly LMS2-4), TGFbeta, and also cancer stemness inhibitors for CMS4 (and possibly LMS5). The gene discussed is MYC; the disease is cancer.